Bifunctional STAT Degraders for Targeted Protein Elimination

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for diseases such as hyperplasia and cancer, particularly breast cancer, face challenges due to non-specific effects and the inability to effectively target and modulate proteins like transcription factors.

Innovation Solution

Development of novel bifunctional compounds that recruit STAT proteins to E3 ubiquitin ligases for degradation, allowing for targeted ubiquitination and inhibition of STAT proteins.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments are used for diseases such as hyperplasia and cancer, then treatment can be provided, but non-specific effects and inability to target transcription factors limit effectiveness

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidability to target specific proteins

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The treatment approach is segmented into two distinct components: a STAT protein-binding ligand and an E3 ubiquitin ligase-binding ligand. These segments are combined in a bifunctional compound to achieve specific targeting of STAT proteins through the proteasome degradation pathway, resolving the contradiction between treatment effectiveness and target specificity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The bifunctional compound acts as an intermediary that bridges the STAT protein and the E3 ubiquitin ligase. By containing both binding ligands, it mediates the recruitment of STAT proteins to E3 ubiquitin ligases, enabling targeted degradation and overcoming the limitation of non-specific effects in current treatments.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Adaptability or versatility

If conventional therapy is used, then broad treatment coverage is achieved, but specificity in modulating transcription factors like STAT proteins is lost

Engineering Contradiction:

Improvetreatment coverageVSAvoidtargeting precision

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The therapeutic agent is divided into two functional segments: one that binds STAT proteins with high specificity and another that recruits E3 ubiquitin ligases. This segmentation allows the compound to maintain broad treatment coverage while achieving precise targeting of transcription factors through the degradation pathway.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The bifunctional compound functions as a composite therapeutic agent combining two distinct liganding functions. This composite structure enables simultaneous achievement of broad treatment coverage and high targeting precision for STAT proteins, resolving the contradiction between versatility and measurement precision.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds effectively degrade STAT proteins, offering a broad range of pharmacological activities and potential therapeutic benefits in treating diseases associated with aberrant STAT protein regulation.

Implementation Method 1

The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases

Methodology Applied

Scientific EffectUbiquitination:

Implementation Method 2

UBP plays a key role in the degradation of short-lived and regulatory proteins

Methodology Applied

Scientific EffectProteasome degradation:

Data Source

PatentUS20250059221A1STAT degraders and uses thereof

Publication Date: 2025.02.20 KYMERA THERAPEUTICS INC

AI summary

The present invention provides compounds, compositions thereof, and methods of using the same.